<DOC>
	<DOCNO>NCT00003977</DOCNO>
	<brief_summary>RATIONALE : Vaccines may make body build immune response kill tumor cell . PURPOSE : Phase I trial study effectiveness vaccine therapy treat patient recurrent persistent cervical cancer treat surgery radiation therapy .</brief_summary>
	<brief_title>Vaccine Therapy Treating Patients With Recurrent Persistent Cervical Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Evaluate alternate vaccination lipidated human papillomavirus 16 E7 peptide ( HPV-16 E7 ) autologous dendritic cell pulse immunogenic HPV-16 E7 term toxicity , immunologic reactivity , therapeutic efficacy patient recurrent persistent cervical cancer . OUTLINE : This dose-escalation study dendritic cell-human papillomavirus 16 E7 ( HPV-16 E7 ) peptide vaccine . Patients undergo leukapheresis obtain peripheral blood mononuclear cell activation dendritic cell day 0 28 . Patients receive lipidated HPV-16 E7 peptide vaccine subcutaneously day 1 14 dendritic cell-HPV-16 E7 peptide vaccine IV 15-30 minute day 7 21 . Treatment continue absence disease progression unacceptable toxicity . Patients stable disease complete partial response may receive one additional treatment course , begin 6 week end first course . Cohorts 3-9 patient receive escalate dos dendritic cell-HPV-16 E7 peptide vaccine . The maximum tolerate dose define dose precede 2 6 patient experience dose limit toxicity . A parallel cohort patient receive dendritic cell-HPV-16 E7 peptide vaccine IV 15-30 minute day 7 14 , receive lipidated HPV-16 E7 peptide . Patients follow one week . PROJECTED ACCRUAL : Approximately 27 patient accrue study rate 15 patient per year .</detailed_description>
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven recurrent persistent cervical cancer amenable surgery radiotherapy Measurable evaluable disease HLAA2 positive PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : More 3 month Hematopoietic : WBC great 3,000/mm^3 Platelet count great 100,000/mm^3 Hemoglobin great 8.0 g/dL No coagulation disorder Hepatic : Bilirubin le 2.0 mg/dL SGOT le 4 time upper limit normal Renal : Creatinine le 1.5 mg/dL OR Creatinine clearance great 75 mL/min Cardiovascular : No major cardiovascular illness Pulmonary : No major pulmonary illness Other : HIV negative Hepatitis B surface antigen negative No active systemic infection Not pregnant Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : At least one month since prior biologic therapy Chemotherapy : At least one month since prior chemotherapy Endocrine therapy : At least one month since prior endocrine therapy No concurrent steroid therapy Radiotherapy : See Disease Characteristics At least one month since prior radiotherapy Surgery : See Disease Characteristics At least one month since prior surgery</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2003</verification_date>
	<keyword>stage III cervical cancer</keyword>
	<keyword>recurrent cervical cancer</keyword>
	<keyword>stage IB cervical cancer</keyword>
	<keyword>stage IIB cervical cancer</keyword>
	<keyword>stage IVB cervical cancer</keyword>
	<keyword>stage IA cervical cancer</keyword>
	<keyword>stage IIA cervical cancer</keyword>
	<keyword>stage IVA cervical cancer</keyword>
</DOC>